创新药概念股持续走强，华纳药厂涨超10%创历史新高

Core Viewpoint - The innovative drug concept stocks are experiencing significant growth, with Warner Pharmaceuticals rising over 10% to reach a historical high, indicating a strong market interest in this sector [1] Group 1: Market Performance - Warner Pharmaceuticals has seen a rise of over 10%, achieving a historical high [1] - Several companies, including Celgene Medical (603716), Lianhuan Pharmaceutical (600513), Qianyuan Pharmaceutical (300254), and Haizhi Pharmaceutical (002653), have reached their daily price limits [1] Group 2: Industry Valuation - Goldman Sachs highlights that the overall market capitalization of Chinese biotech companies is only 14%-15% of their American counterparts, despite contributing nearly 33% to global innovation [1] - This disparity suggests that the Chinese innovative drug sector is still in a "value trap" phase, with a global capital reassessment just beginning [1] Group 3: Investment Trends - There is a notable influx of dark pool funds into these stocks, indicating increased investor interest and potential for future growth [1]